$AIFF

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

GlobeNewswire Inc. · 8/5/2026, 11:45:00 AM

Firefly Neuroscience announced a nearly four-fold increase in TMS center customer clinical assessments using its FDA-cleared Evoke AI-powered EEG/ERP platform. The platform combines quantitative EEG and event-related potentials to help clinicians assess brain activity and tailor treatments for psychiatric and behavioral health conditions. The company continues to expand adoption among TMS centers while building its proprietary database of over 200,000 EEG/ERP brain scans.

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuroprotective Peptides

GlobeNewswire Inc. · 7/28/2026, 11:50:00 AM

Firefly Neuroscience (NASDAQ: AIFF) and Next Health announced a strategic partnership to launch a precision cognitive health platform combining Firefly's FDA-cleared AI-powered EEG/ERP brain biomarker technology with personalized cognitive peptide protocols. The collaboration follows an FDA Advisory Committee's recommendation to ease compounding restrictions for six peptides, including Epitalon and Semax, which have shown potential neuroprotective and cognitive-supportive properties in scientific literature.

Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients

GlobeNewswire Inc. · 6/20/2025, 11:45:00 AM

Firefly Neuroscience researchers have developed a new method to accurately differentiate between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia in Alzheimer's patients using a combination of EEG/ERP and volumetric MRI data.

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Benzinga · 5/5/2025, 11:45:00 AM

Firefly Neuroscience, an AI company, has acquired Evoke Neuroscience, a medical device company, to expand its proprietary database, patent portfolio, and commercial reach. The acquisition marks a significant step towards Firefly's goal of building a foundation model of the human brain.

Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million

GlobeNewswire Inc. · 2/21/2025, 1:00:00 PM

Firefly Neuroscience, Inc. has received $8.8 million from the exercise of warrants, which will be used for general working capital purposes, including the development of its FDA-cleared Brain Network Analytics (BNA™) technology platform.